N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of Alzheimer's disease
View Patent ↗The present invention is directed to compounds which are inhibitors of the beta-secretase enzyme and which are useful in the treatment or prevention of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
1. A compound of the formula I:
wherein:
R 1 is selected from the group consisting of:
(1) C 1-6 alkyl, unsubstituted or substituted with —OR 5 or —S(O) 2 —C 1-6 alkyl,
(2) hydrogen,
(3) phenyl, and
(4) benzyl;
R 2 is selected from the group consisting of:
(1) R 4 —S(O) p —,
wherein R 4 is independently selected from the group consisting of:
(a) —C 1-6 alkyl, which is unsubstituted or substituted with 1-6 fluoro,
(b) phenyl, and
(c) benzyl,
(2) R 4 —S(O) p N(R 5 )—,
wherein R 5 is independently selected from the group consisting of:
(a) hydrogen,
(b) —C 1-6 alkyl, which is unsubstituted or substituted with 1-6 fluoro,
(c) —C 3-6 cycloalkyl which is unsubstituted or substituted with methyl,
(d) phenyl, which is unsubstitued or substituted with halo or methoxy, and
(e) benzyl,
(3) —CN,
(4) —C 1-6 alkyl-CN,
(5) halogen,
(6)
wherein R 8a and R 8b are independently selected from the group consisting of:
(a) hydrogen,
(b) —CN,
(c) halo,
(d) —C 1-6 alkyl,
(e) —O—R 5 ,
(f) —S—R 5 ,
(g) —CO 2 R 5 , and
(h) tetrazolyl,
(7)
wherein n is 1, 2, 3 or 4;
R 3 is selected from the group consisting of:
R 6a , R 6b , and R 6c are independently selected from the group consisting of:
(1)hydrogen,
(2)halogen,
(3) —OR 5 ,
(4) —SR 5 , and
(5) —C 1-6 alkyl;
R 7 is selected from the group consisting of a bond, —CH=CH—, —O—, —S—, and —NH—;
R 9 and R 10 are independently selected from the group consisting of:
(1) hydrogen,
(2) C 1-6 alkyl, unsubstituted or substituted with —CN or 1-4 halo,
(3) —C 3-6 cycloalkyl,
(4) phenyl, which is unsubstitued or substituted with halo or methoxy, and
(5) benzyl,
or R 9 and R 10 may be joined together to form a pyrrolidine or piperidine ring which is unsubstituted or substituted with benzyl, —OR 5 or 1-4 halo;
m is independently 0, 1, or 2;
p is independently 0, 1, or 2,
and pharmaceutically acceptable salts thereof.
2. The compound of claim 1 wherein R 1 is C 1-6 alkyl.
3. The compound of claim 1 wherein R 1 is methyl.
4. The compound of claim 1 wherein R 1 is ethyl.
5. The compound of claim 1 wherein R 2 is:
R 4 —S(O) 2 —NR 5 —
and wherein R 4 is selected from the group consisting of:
(1) C 1-6 alkyl,
(2) phenyl, and
(3) benzyl;
R 5 is selected from the group consisting of:
(1) C 1-6 alkyl,
(2) phenyl,
(3) benzyl, and
(4) hydrogen.
6. The compound of claim 1 wherein R 3 is:
and wherein R 5 is methyl, R 6a is H or F, R 6b and R 6c are hydrogen.
7. The compound of claim 1 wherein R 3 is:
8. The compound of claim 1 wherein R 9 is hydrogen.
9. The compound of claim 1 wherein R 10 is C 1-6 alkyl.
10. The compound of claim 1 wherein R 10 is iso-butyl.
11. A compound which is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
12. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 and a pharmaceutically acceptable carrier.